PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Extreme Weather Alert: Revolutionary New Dry Skin Cream Soars Above Accepted Industry Standard

How well do dry skin care lotions fare against each other when tested for the ability to keep one's skin moisturized, especially during our constantly changing weather conditions?

2014-04-12
BEVERLY HILLS, CA, April 12, 2014 (Press-News.org) How well do dry skin care lotions fare against each other when tested for the ability to keep one's skin moisturized, especially during our constantly changing weather conditions? A new study, which included the shielding lotion Skin MD Natural had surprising results according to Germaine Muniz at Cantor Research Laboratories.

Cantor Research Laboratories discovered that when Skin MD Natural skin lotion treatment was applied to dry skin, it actually increased the skin's ability over time to retain moisture. All other products tested, including Vaseline Petroleum Jelly (considered to be the ultimate in preventing moisture loss), decreased in their ability to maintain skin moisture.

The lab, located in Valley Cottage, NY, completed its findings from the Trans-Epidermal Water Loss (TEWL) study on the shielding lotion, showing over the course of one hour with washing, that Skin MD Natural continued to increase its moisturizing abilities whereas Vaseline Petroleum Jelly and all other skin care products that have ever been tested diminished. "Skin MD Natural dry skin lotion not only stopped but actually reversed the loss of vital natural moisture that gives skin it's elasticity and youthfulness, unlike any other product we have ever tested," Germaine Muniz at Cantor Research Laboratories stated.

Dr. Lisa Benest, a board certified dermatologist in Southern California explains why shielding lotions are superior to artificial moisturizers: "A shielding lotion is a lotion that provides a natural barrier on top of the skin to protect it from outside chemicals and irritants. In addition it also acts to keep the moisture and the oils in the skin so that the skin can heal itself. Shielding lotions not only protect the skin's barrier but they restore the moisture to the skin allowing the skin to continue to moisturize itself, so that your skin does not become addicted on the moisturizer, ultimately curing the dry skin problem."

"This study reconfirms that the shielding properties of Skin MD Natural are better across the board than the products currently on the market," says Enrique Alabata, director of research and development for a world-class cosmetics formulations company. "The feel of Skin MD Natural is very light on the skin compared to products performing similarly like Vaseline Petroleum Jelly, cocoa or Shea butter, or mineral oil. It really does do what it says it does, making it a premier anti-aging treatment."

Backed by solid research and dermatology use, this new category of moisturizer, shielding lotion is carving a niche as a leading dry skin treatment that really works.

21st Century Formulations, Inc. tested countless formulations and spent years developing Skin MD Natural Shielding Lotion to ensure it would deliver on its promise to help heal dry skin and protect healthy skin. Skin MD Natural uses a special blend of six vitamins and herbs that naturally strengthen the skin's barrier restoring its function. The result is that skin will require much less lotion over time and not more like conventional lotions.

Skin MD Natural is the top selling natural shielding lotion that uses only the finest quality ingredients. To learn more about how Skin MD Natural can heal dry skin visit http://www.skinmdnatural.com

21st Century Formulations, Inc. tested countless formulations and spent years developing Skin MD Natural Shielding Lotion to ensure it would deliver on its promise to help heal dry skin and protect healthy skin. Skin MD Natural uses a special blend of six vitamins and herbs that naturally strengthen the skin's barrier restoring its function. The result is that skin will require much less lotion over time and not more like conventional lotions.


ELSE PRESS RELEASES FROM THIS DATE:

Hepatitis C treatment cures over 90 percent of patients with cirrhosis

2014-04-12
SAN ANTONIO, Texas (April 12, 2014) — Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute. Historically, hepatitis C cure rates in patients with cirrhosis (liver scarring) have been lower than 50 percent and the treatment was not safe for many of these patients. Hepatitis C virus is the No. 1 driver of cirrhosis, liver transplants ...

Obeticholic acid produces meaningful biochemical and clinical improvements in PBC cirrhosis patients

2014-04-12
London, UK, Saturday 12 April 2014: Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC. Obeticholic acid at both a 10 mg dose and a 5 mg dose titrated to 10 mg, met the trial's primary composite endpoint ...

Three new studies help clarify optimal use of combination therapy in chronic hepatitis B patients

2014-04-12
London, UK, Saturday 12 April 2014: Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB). "Together these ground-breaking data will go a long way to influencing future CHB treatment guidelines," said EASL's Educational Councillor Professor Cihan Yurdaydin from the Department of Gastroenterology, University of Ankara, Turkey. In the first study , CHB patients ...

New Chinese herbal medicine has significant potential in treating hepatitis C

2014-04-12
London, UK, Saturday 12 April 2014: Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' lifecycle.[i] SBEL1 is a compound isolated from Chinese herbal medicines that was found to inhibit HCV activity by approximately 90%. SBEL1 is extracted from a herb found in certain regions of Taiwan and Southern China. In Chinese medicine, it is used to treat sore throats and inflammations. The function of SBEL1 ...

Impressive SVR12 data for once-daily combination to treat HCV genotype 1 patients

2014-04-12
London, UK, Saturday 12 April 2014: Results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400mg and the NS5A inhibitor ledipasvir (LDV) 90mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection have been presented at the International Liver CongressTM 2014. "With cure rates well in excess of 90% with as little as eight weeks of treatment for some patients, these data represent ...

Gut microbiota may play a role in the development of alcoholic liver disease

2014-04-12
London, UK, Saturday 12 April 2014: Exciting new data presented today at the International Liver Congress™ 2014 shows that the gut microbiota has a potential role in the development of alcoholic liver disease (ALD).1 Though an early stage animal model, the French study highlights the possibility of preventing ALD with faecal microbiota transplantation – the engrafting of new microbiota, usually through administering human faecal material from a healthy donor into the colon of a recipient.2 In the study, two groups of germ-free mice received gut microbiota transplants ...

Low vitamin D linked to fatty liver disease in UK children

2014-04-12
London, UK, Saturday 12 April 2014: A UK study[i] investigating the link between low vitamin D status and non-alcoholic fatty liver disease (NAFLD) in British children has identified a genetic variant associated with the disease's severity. The research, conducted by the King's College Hospital Paediatric Liver Centre and the University of Surrey's School of Biosciences and Medicine, and funded by the Children's Liver Disease Foundation retrospectively analysed the medical records of 120 paediatric patients with NAFLD. The findings could carry significant implications ...

New advances in HCC diagnosis, staging and treatment all predicted to improve patient outcomes

2014-04-12
London, UK, Saturday 12 April 2014: Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC). "Human hepatocellular carcinoma is one of the most prevalent cancers worldwide and the second most frequent cause of cancer-related death," said EASL's Scientific Committee Member Dr Helen Reeves Senior Lecturer & Honorary Consultant Gastroenterologist at Newcastle Hospitals NHS Foundation Trust, ...

New interferon-free, all-oral 3D regimen achieves high SVR in chronic HCV genotype 1 patients

2014-04-12
London, UK, Saturday 12 April 2014: The new interferon-free, all-oral, three direct-acting-antiviral (3D) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1 (GT1); according to the results of three studies presented today at the International Liver CongressTM 2014. The 3D regimen consists of the HCV NS3/4A protease inhibitor ABT-450 dosed with ritonavir, the NS5A inhibitor ABT-267, and the NS5B RNA polymerase inhibitor ABT-333. "Using this investigational ...

New data for HCV genotype 4 patients with simeprevir- and sofosbuvir-based regimens

2014-04-12
London, UK, Saturday 12 April 2014: Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented today at the International Liver CongressTM 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon and ribavirin (followed by 12 or 36 weeks of peginterferon and ribavirin) was effective and well tolerated in hepatitis C virus (HCV) genotype 4-infected patients, consistent with previous observations in HCV genotype 1-infected patients. Overall, 65.4% of patients achieved SVR12 (82.9% of treatment-naïve, 86.4% ...

LAST 30 PRESS RELEASES:

Soccer heading damages brain regions affected in CTE

Autism and neural dynamic range: insights into slower, more detailed processing

AI can predict study results better than human experts

Brain stimulation effectiveness tied to learning ability, not age

Making a difference: Efficient water harvesting from air possible

World’s most common heart valve disease linked to insulin resistance in large national study

Study unravels another piece of the puzzle in how cancer cells may be targeted by the immune system

Long-sought structure of powerful anticancer natural product solved by integrated approach

World’s oldest lizard wins fossil fight

Simple secret to living a longer life

Same plant, different tactic: Habitat determines response to climate

Drinking plenty of water may actually be good for you

Men at high risk of cardiovascular disease face brain health decline 10 years earlier than women

Irregular sleep-wake cycle linked to heightened risk of major cardiovascular events

Depression can cause period pain, new study suggests

Wistar Institute scientists identify important factor in neural development

New imaging platform developed by Rice researchers revolutionizes 3D visualization of cellular structures

To catch financial rats, a better mousetrap

Mapping the world's climate danger zones

Emory heart team implants new blood-pumping device for first time in U.S.

Congenital heart defects caused by problems with placenta

Schlechter named Cancer Moonshot Scholar

Two-way water transfers can ensure reliability, save money for urban and agricultural users during drought in Western U.S., new study shows

New issue of advances in dental research explores the role of women in dental, clinical, and translational research

Team unlocks new insights on pulsar signals

Great apes visually track subject-object relationships like humans do

Recovery of testing for heart disease risk factors post-COVID remains patchy

Final data and undiscovered images from NASA’s NEOWISE

Nucleoporin93: A silent protector in vascular health

Can we avert the looming food crisis of climate change?

[Press-News.org] Extreme Weather Alert: Revolutionary New Dry Skin Cream Soars Above Accepted Industry Standard
How well do dry skin care lotions fare against each other when tested for the ability to keep one's skin moisturized, especially during our constantly changing weather conditions?